Calcifediol monohydrate
产品说明书
 |
同义名 : | 25-hydroxy Vitamin D3 monohydrate |
| CAS号 : | 63283-36-3 | |
| 货号 : | A443037 | |
| 分子式 : | C27H46O3 | |
| 纯度 : | 99%+ | |
| 分子量 : | 418.652 | |
| MDL号 : | MFCD08600001 | |
| 存储条件： |
Pure form Sealed in dry,Store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(119.43 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), a major circulating metabolite of vitamin D3, is a potent VDR inhibitor. Calcifediol in either liposomes or ethanolic solution has no effect on the release of the proinflammatory cytokine KC from Pseudomonas-infected murine epithelial cells. Treatment of infected, human bronchial 16-HBE cells with Calcifediol liposomes results in a significant reduction in bacterial survival[2]. The safer pharmacokinetic of the recent modified-release (MR) formulation of calcifediol was effective in replenishing 25(OH)D levels with minimal impact on vitamin D catabolism and fibroblast-growth factor-23 (FGF-23) activation[3]. The inhibitory effects induced by VDR overexpression could be reversed by the VDR inhibitor, calcifediol[4]. Extended-release calcifediol (ERC) is an orally administered prohormone of active vitamin D (1,25-dihydroxyvitamin D [1,25D]) designed to safely and sufficiently increase serum total 25-hydroxyvitamin D (25D) to reduce elevated parathyroid hormone (PTH) in patients with non-dialysis-chronic kidney disease (ND-CKD)[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.39mL 0.48mL 0.24mL |
11.94mL 2.39mL 1.19mL |
23.89mL 4.78mL 2.39mL |
| 参考文献 |
|---|